Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.
G. R. Hudes(Fox Chase Cancer Center), C McAleer, Naomi B. Haas(University of Pennsylvania), Eric A. Ross(Fox Chase Cancer Center), Carine Khater, Leonard G. Gomella(Thomas Jefferson University), Richard E. Greenberg, Bruce J. Giantonio(Northwestern University), Faith E. Nathan, M Cornfield, Samuel Litwin, Susan K. Roethke
Cited by 273
Related Papers
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
|Nature Medicine|2019|521
Association of Type and Location of<i>BRCA1</i>and<i>BRCA2</i>Mutations With Risk of Breast and Ovarian Cancer
|JAMA|2015|507
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial
|Nature Medicine|2022|491
Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer
|Clinical Cancer Research|2021|358